GLP-1R agonists show promise as a therapeutic agent to lower intracranial pressure in rodents.</jats:p

Botfield, Hannah F

Gonzalez, Ana Maria

Hagen, Snorre M

Hodson, David J

Jensen, Rigmor H

Mitchell, James L

Sinclair, Alexandra J

Uldall, Maria S

Westgate, Connar S J

Current therapies for reducing raised intracranial pressure (ICP) under conditions such as idiopathic intracranial hypertension or hydrocephalus have limited efficacy and tolerability. Thus, there is a pressing need to identify alternative drugs. Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat diabetes and promote weight loss but have also been shown to affect fluid homeostasis in the kidney. We investigated whether exendin-4, a GLP-1R agonist, is able to modulate cerebrospinal fluid (CSF) secretion at the choroid plexus and subsequently reduce ICP in rats. We used tissue sections and cell cultures to demonstrate expression of GLP-1R in the choroid plexus and its activation by exendin-4, an effect blocked by the GLP-1R antagonist exendin 9-39. Acute treatment with exendin-4 reduced Na(+)- and K(+)-dependent adenosine triphosphatase activity, a key regulator of CSF secretion, in cell cultures. Finally, we demonstrated that administration of exendin-4 to female rats with raised ICP (hydrocephalic) resulted in a GLP-1R-mediated reduction in ICP. These findings suggest that GLP-1R agonists can reduce ICP in rodents. Repurposing existing GLP-1R agonist drugs may be a useful therapeutic strategy for treating raised ICP.</p

University of Birmingham Research Portal

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

English

Hannah F. Botfield

Maria S. Uldall

Connar S. J. Westgate

James L. Mitchell

Snorre M. Hagen

Ana Maria Gonzalez

David J. Hodson

Rigmor H. Jensen

Alexandra J. Sinclair

Crossref

Science Translational Medicine

Current therapies for reducing raised intracranial pressure (ICP) under conditions such as idiopathic intracranial hypertension or hydrocephalus have limited efficacy and tolerability. Thus, there is a pressing need to identify alternative drugs. Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat diabetes and promote weight loss but have also been shown to affect fluid homeostasis in the kidney. We investigated whether exendin-4, a GLP-1R agonist, is able to modulate cerebrospinal fluid (CSF) secretion at the choroid plexus and subsequently reduce ICP in rats. We used tissue sections and cell cultures to demonstrate expression of GLP-1R in the choroid plexus and its activation by exendin-4, an effect blocked by the GLP-1R antagonist exendin 9-39. Acute treatment with exendin-4 reduced Na+- and K+-dependent adenosine triphosphatase activity, a key regulator of CSF secretion, in cell cultures. Finally, we demonstrated that administration of exendin-4 to female rats with raised ICP (hydrocephalic) resulted in a GLP-1R-mediated reduction in ICP. These findings suggest that GLP-1R agonists can reduce ICP in rodents. Repurposing existing GLP-1R agonist drugs may be a useful therapeutic strategy for treating raised ICP.</p

Copenhagen University Research Information System

http://pure-oai.bham.ac.uk/ws/files/42427680/aan0972_ArticleContent_last_MM_july_31_Final_HFB.pdf

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

Abstract

Similar works

Full text

Available Versions

University of Birmingham Research Portal

University of Birmingham Research Portal

Crossref

Copenhagen University Research Information System